![]()
|
|
||||||||
J. Biol. Chem., Vol. 276, Issue 47, 44193-44202, November 23, 2001
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
,
,From the Institute of Molecular and Cell Biology, 30 Medical Drive, Singapore 117609, Republic of Singapore
Received for publication, June 25, 2001, and in revised form, September 14, 2001
| |
ABSTRACT |
|---|
|
|
|---|
In Caenorhabditis elegans,
fem-1, fem-2, and fem-3 play pivotal roles in
sex determination. Recently, a mammalian homologue of the C. elegans sex-determining protein FEM-1, F1A Apoptosis, or programmed cell death
(PCD),1 plays important roles
in tissue homeostasis and development in essentially all multicellular
organisms (1, 2). Genetic analyses of the PCD pathway in
Caenorhabditis elegans have successfully identified key
regulatory genes that define the core machinery of cell death. Orthologues of the apoptosis genes of C. elegans have
subsequently been identified in other organisms including mammals (3,
4), suggesting that the molecular strategies that regulate the
fundamental aspects of this important biological process are likely to
be conserved across species.
The molecular strategies that are involved in sex determination among
species, however, are thought to be quite diverse (5, 6). Indeed, genes
in the sex-determining pathway are known to be rapidly diverged even
between two closely related species, C. elegans and
Caenorhabditis briggsae (7, 8). In C. elegans, many genes have been identified that affect sexual fate. One of the key
steps in the sex determination pathway in C. elegans is regulated by three fem genes, fem-1,
fem-2, and fem-3 (8, 9). Loss-of-function
mutations in any one of the fem genes prevent all aspects of
male development and transform both males and hermaphrodites into
females (9, 10). fem-1 encodes a protein with ankyrin repeats (11), and fem-2 encodes a serine/threonine protein
phosphatase of the PP2C type (12), which interacts directly with FEM-3
(13, 14), a protein without any recognizable functional motif.
F1A Despite their exclusive roles in masculinizing somatic tissues in males
and regulating the production of male germ cells (8, 9), FEM-1 and
FEM-2 proteins are expressed throughout development in all somatic
tissues at equivalent levels in both sexes (12, 19). This observation
raises the question as to whether these proteins would have additional
functions other than sex determination. Although there is no evidence
to link F1A To test our hypothesis, we initiated a search for putative mammalian
homologues of fem genes. A search in the GenBankTM data base revealed a human cDNA that encodes a full-length protein, which we named hFEM-2, that exhibits extensive amino acid sequence similarity to FEM-2 (28% amino acid identity). hFEM-2 exhibited enzymatic characteristics of the PP2C type similar to those for FEM-2.
Like FEM-2, hFEM-2 associates with FEM-3, whereas a related PP2C
phosphatase, PP2C The putative human homologue of fem-2 shares 79% amino acid
identity with the rat Ca2+/calmodulin-dependent
protein kinase phosphatase (rCaMKPase) that was recently cloned from
rat brain (21). CaM-dependent protein kinases are
multifunctional protein kinases that control a variety of cellular
functions including apoptosis (22-27). CaM kinase II is activated
through autophosphorylation, whereas CaM kinase I and IV are activated
through phosphorylation by upstream
Ca2+/calmodulin-dependent protein kinase
kinases (23). CaM kinase phosphatase was initially purified from rat
brain using a synthetic peptide corresponding to the
autophosphorylation site of CaM kinase II (28). The rCaMKPase
dephosphorylated and deactivated CaM kinase II activated by
autophosphorylation (28), and was later shown to be able to
dephosphorylate CaM kinases I and IV activated upon phosphorylation by
CaM kinase kinases (28, 29). We show that FEM-2, hFEM-2, and rCaMKPase
mediate caspase-dependent cell death when overexpressed in
mammalian cells. We also demonstrate that FEM-2 and its human homologue
can dephosphorylate autophosphorylated CaM kinase II efficiently
in vitro. Hence, FEM-2 and its mammalian homologues are
evolutionarily conserved CaM kinase phosphatases that may play a role
in apoptosis signaling.
Reagents and Cell Lines--
Mono- and polyclonal
antibodies against the Myc epitope (9E10, A14), monoclonal antibody
against the HA epitope (F7), and polyclonal antibody against
poly(ADP-ribose) polymerase (PARP) (A20) were obtained from Santa Cruz
Biotechnology. 293T human embryo kidney cells, NIH3T3 fibroblast cells,
and HeLa cells were originally from the American Type Culture
Collection (ATCC). tumor necrosis factor-sensitive MCF7 breast
carcinoma cells were maintained as described previously (15, 16).
Ca2+/calmodulin-dependent kinase II (CaM kinase
II) was obtained from Calbiochem.
Construction of Plasmids--
Plasmids containing the cDNAs
for fem-1, fem-2, and fem-3 were
kindly provided by Dr. Andrew Spence (University of Toronto, Toronto,
Ontario, Canada). The cDNA for rat Ca2+/calmodulin
kinase phosphatase was kindly provided by Dr. Hitoshi Fujisawa
(Asahikawa Medical College, Asahikawa, Hokkaido, Japan). cDNA fragments for hFEM-2 and hPP2C Northern Blot Analysis--
Human multiple tissue Northern blots
(CLONTECH) were hybridized with a
32P-labeled probe corresponding to the
NH2-terminal 295-base pair coding region of hFEM-2 using
ExpressHybTM hybridization solution (CLONTECH)
according to the instructions of the manufacturer.
Immunofluorescence Assay--
MCF-7 cells were transfected at
70% confluence on sterile glass coverslips using LipofectAMINETM with
2 µg of Myc-hFEM-2, and 16 h later cells were harvested and
washed gently with PBS. Cells were then fixed with methanol for 5 min
at Co-immunoprecipitation--
Co-immunoprecipitation analyses were
performed as described (15, 16). Briefly, 293T cells seeded on a 100-mm
plate at 80% confluence were transfected with 5 µg each of
expression plasmids driven by the CMV promoter (pXJ40) (15, 16)
encoding the indicated NH2-terminal HA- and Myc-tagged
proteins using LipofectAMINETM (Life Technologies, Inc.). 16 h
after transfection, the cells were harvested and lysed in 1 ml of lysis
buffer (50 mM HEPES, pH 7.6, 250 mM NaCl, 0.1%
Nonidet P-40, 5 mM EDTA, 1 mM PMSF, 50 µg/ml
aprotinin, and 10 µg/ml leupeptin). An aliquot (1%) of the cell
lysates (1 ml) was fractionated on SDS-PAGE for visualization of the
expression of proteins. The remaining cell lysates were subjected to
immunoprecipitation using 1 µg of polyclonal anti-Myc antibody. 20 µl of 1:1 slurry of protein A-agarose was added after 1 h and
incubated for another 1 h at 4 °C. The agarose beads were washed once in 1 ml of lysis buffer, two times in 1 ml of lysis buffer
containing 500 mM NaCl, and once in 1 ml of lysis buffer before fractionation on SDS-PAGE followed by Western blotting analyses.
In Vitro Binding Analysis--
Sequence encoding hFEM-2 was
excised from pXJ40 vector and cloned in-frame into the glutathione
S-transferase (GST) fusion protein bacterial expression
vector pGEX-TK4E. The plasmids were transformed into the
Escherichia coli strain BL21. GST and GST fusion protein
were prepared by standard methods (30), and the recombinant proteins
were immobilized on glutathione-agarose beads. Labeled proteins were
prepared by in vitro transcription/translation of
pXJ-HA-constructs using the TNT T7-coupled reticulocyte lysate system
(Promega) in the presence of [35S]methionine. The
integrity of the 35S-labeled proteins was verified by
SDS-PAGE. For in vitro protein interaction, equal amounts of
total 35S -labeled lysate (7 × 105 cpm of
trichloroacetic acid-precipitable counts) were diluted into 0.2 ml of
GST binding buffer (20 mM Tris, pH 7.5, 1 mM
EDTA, 150 mM NaCl, 0.2% Nonidet P-40) and incubated for
1 h with the various GST fusion proteins immobilized on the beads
(~2 µg). Samples were subsequently washed six times with binding
buffer and boiled for 3 min in loading buffer before fractionation on 10% SDS-PAGE. Bound proteins were visualized by autoradiography.
Phosphatase Assay--
293T cells seeded on 150-mm plates at
80% confluence were transfected with 10 µg of expression plasmids
driven by the CMV promoter (pXJ40) (15, 16) encoding the indicated
NH2-terminal Myc-tagged proteins using LipofectAMINETM
(Life Technologies, Inc.). 24 h after transfection, cells were
harvested and lysed in 1 ml of storage buffer (50 mM Tris,
pH 7.6, 150 mM NaCl, 0.1 mM EGTA, 0.1%
Autophosphorylation of CaMKII--
Autophosphorylation of CaMKII
(Calbiochem) was performed as described (28). Briefly, CaMKII (10 µg/ml) was autophosphorylated at 30 °C for 1 min in a reaction
mixture containing 40 mM Hepes-NaOH, pH 8.0, 5 mM Mg(CH3CO2)2, 0.1 mM EGTA, 5 µM calmodulin, 0.4 mM CaCl2, 0.02% Tween 20, and 0.33 µM
[ Dephosphorylation of CaMKII--
Dephosphorylation of CaMKII was
performed as described (28). Dephosphorylation of
[32P]CaMKII was carried out at 30 °C for 20 min in a
30-µl reaction mixture containing ~2 µg of GST, GST-rCaMKPase,
GST-hFEM-2, GST-FEM-2, or GST-PP2C Nuclear Staining of (EGFP)-expressing Cells--
HeLa cells were
seeded onto glass coverslips at 70% confluence and transfected with
pEGFP, pEGFP-FEM-2, or pEGFP-PP2C Apoptosis Assay--
Apoptosis assays were performed as
described (15, 16). Briefly, HeLa, MCF7, or NIH3T3 cells were
transiently co-transfected with 2 µg each of the expression plasmids
or vector and 0.5 µg of pCMV- PARP Cleavage Assay--
For detection of PARP cleavage, HeLa
cells cultured on 100-mm dishes were transiently transfected with the
various pXJ-Myc constructs (10 µg). Whole cell extracts were prepared
by lysing the cells in 0.2 ml of lysis buffer (50 mM HEPES,
pH 7.6, 250 mM NaCl, 0.1% Nonidet P-40, 5 mM
EDTA, 1 mM PMSF, 50 µg/ml aprotinin, and 10 µg/ml
leupeptin). The extracts were fractionated on SDS-PAGE followed by
Western blotting analyses using PARP-specific antibody (A20).
Identification, Cloning, and Tissue mRNA Distribution of
hFEM-2--
To identify mammalian homologues of fem-2 and
fem-3, we searched the GenBankTM data base for cDNAs
encoding proteins with homology to these genes. No gene with
significant similarity to fem-3 was found. However, the
amino acid sequence predicted by analysis of an open reading frame
(ORF) of a cDNA clone, kiaa0015 (GenBankTM accession no. D13640),
derived from randomly sampled cDNA clones prepared from human
immature myeloid cell line KG-1 (31), showed significant homology to
FEM-2. The kiaa0015 clone contained a single long ORF encoding a
protein of 454 amino acids (Fig.
1A). The 5' and 3' regions
adjacent to the ORF contain stop codons in all three reading frames
preceding the predicted translation start site and subsequent to the
end of the ORF, suggesting that it encodes a full-length protein. Using
the 5' and 3' sequence information derived from this clone, several
independent cDNA clones encoding kiaa0015 product were generated by
PCR from double-stranded cDNAs prepared from human spleen
(CLONTECH). Three of the independent clones
were sequenced completely in both directions, and the deduced amino
acid sequences encoded by the clones were found to be identical to the
sequence encoded by kiaa0015. We named this protein hFEM-2.
hFEM-2 shares relatively high amino acid sequence homology with FEM-2,
with a relatively long amino-terminal extension flanking the catalytic
domain. Over the entire length of the protein, the amino acid identity
between hFEM-2 and FEM-2 is 28%. The degree of similarity is not
uniform over the entire length of the protein. In the catalytic domain,
the two proteins are 30% identical, whereas in the amino-terminal
region, the proteins are 18% identical. The catalytic domains among
different members (
The expression profile of hFEM-2 in human tissues was assessed by
Northern blot analysis. Two transcripts, with estimated length of 6.5 and 3 kb, were detected in all adult tissues studied (Fig.
1B). The level of hFEM-2 mRNA message was variable from tissue to tissue, with the highest expression in testis (Fig. 1B). The subcellular localization of hFEM-2 was assessed in
MCF-7 cells using immunocytochemistry. Myc-tagged hFEM-2 was expressed in MCF-7 cells, and the expression of the protein was detected using
FITC-conjugated Myc antibody, whereas propidium iodide was used to
stain the nuclei. hFEM-2 was consistently found diffusely distributed
in the cytosol with no notable expression in the nucleus (Fig.
1C), suggesting that hFEM-2 is a cytosolic protein.
hFEM-2 Exhibits PP2C Phosphatase Activity toward the Peptide
Substrate (RRA(pT)VA) in Vitro--
As FEM-2 is known to exhibit PP2C
phosphatase activity (13), we proceeded to examine the phosphatase
activity of hFEM-2 in vitro. PP2C is the main enzyme subtype
of the PPM family of serine-threonine phosphatases, and some of its
members include mammalian PP2C hFEM-2 Is a Ca2+/Calmodulin-dependent
Protein Kinase Phosphatase--
A protein initially identified as CaM
kinase phosphatase has recently been purified from rat brain (28).
rCaMKPase was shown to dephosphorylate autophosphorylated CaM kinase
II, whereas phosphorylase kinase, mixed histones, myelin basic protein,
Bacterially expressed rCaMKPase, hFEM-2, FEM-2, and PP2C
When compared with immunoprecipitates of vector transfected cells (Fig.
3B, lane 11), immunoprecipitates of Myc-tagged
hFEM-2 and FEM-2 were able to dephosphorylate CaM kinase II in
vitro (Fig. 3B, lanes 12 and 13),
suggesting that the proteins overexpressed in mammalian cells possess
the ability to constitutively dephosphorylate CaM kinases.
hFEM-2 Specifically Associates with FEM-3--
FEM-2 has been
shown to interact with FEM-3 in the yeast two-hybrid system and
in vitro GST pull-down assay (13). To assess whether hFEM-2
shares functional similarity with FEM-2 in this respect, 293T cells
were transiently co-transfected with plasmids encoding HA-tagged FEM-3
and either Myc-tagged FEM-2, hFEM-2, rCaMKPase, or hPP2C
We next examined the interaction of hFEM-2 with FEM-3 in
vitro. In vitro translated, 35S-labeled
FEM-3 bound to immobilized GST fusion proteins of FEM-2 and hFEM-2 but
not immobilized GST or GST-PP2C hFEM-2 Specifically Associates with F1A
We performed GST pull-down assay to test whether hFEM-2 can
associate with F1A hFEM-2 and FEM-2 Mediate Caspase-dependent Apoptosis in
Mammalian Cells--
To determine whether FEM-2 and its mammalian
homologues are able to mediate apoptosis like FEM-1, we transiently
transfected HeLa cells with mammalian expression plasmids encoding the
various GFP-tagged constructs. 18 h after transfection, cells were
fixed and stained with Hoechst dye and viewed under a fluorescence
microscope. Cells that appeared apoptotic morphologically (rounded cell
appearance) exhibited nuclear condensation and fragmentation, as judged
by Hoechst staining (Fig. 6A).
Overexpression of GFP-FEM-2 and GFP-hFEM-2 but not GFP-hPP2C
To quantitate pro-apoptotic activity, expression constructs of FEM-2
and its mammalian homologues (2 µg) were co-transfected with
Proteolytic cleavage of PARP serves as a marker for the activation of
caspases in cell undergoing apoptosis (35). The cleavage of PARP to the
signature 85-kDa apoptotic fragment was observed in HeLa cells
transiently transfected with hFEM-2, rCaMKPase, and FEM-2, but not
vector-transfected cells (Fig. 6C).
The pro-apoptotic activity of FEM-2 and hFEM-2 was evaluated in two
other mammalian cell lines, NIH3T3 and MCF-7. FEM-2 mediated apoptosis
in all three cell lines, HeLa, NIH3T3, and MCF-7 (data not shown),
whereas hFEM-2 mediated apoptosis in NIH3T3 cells but not MCF-7 cells
(data not shown), suggesting that hFEM-2 exhibits cell
type-dependent pro-apoptotic activity. The protein levels of all the transiently expressed proteins in MCF-7 cells were comparable with that in HeLa and NIH3T3 cells (data not shown); therefore, the lack of pro-apoptotic activity of hFEM-2 in MCF-7 cells
is not a consequence of low protein expression. Transient overexpression of PP2C Apoptosis Mediated by hFEM-2 Is Blocked by Bcl-XL or Dominant
Negative Mutant of Caspase-9--
Apoptosis signaling mediated through
the Fas death receptor is thought to diverge at caspase-8, with one
branch of the pathway leading directly to effector caspase activation
and the other branch communicating with the mitochondria cell death
pathway that are dependent on caspase-9 and Bcl-XL (36, 37). In HeLa cells, the predominant pathway for Fas signaling is
Bcl-XL-dependent (37). To investigate possible pathways by
which CaM kinase phosphatase may be using for mediating the
pro-apoptotic effect in mammalian cells, blocking experiments using
anti-apoptotic Bcl-XL (36) and dominant negative mutants of caspase-8
and caspase-9 were performed. Although dominant negative mutant of
caspase-8, caspase-8-(1-415), was able to block apoptosis
mediated by transient overexpression of Fas or tumor necrosis factor
receptor 1 (Ref. 38 and data not shown), it was only marginally
effective in blocking apoptosis induced by overexpression of hFEM-2 in
HeLa cells (Fig. 7). In contrast, Bcl-XL
and dominant negative mutants of caspase-9, caspase-9-DN (39, 40), were
effective inhibitors of apoptosis induced by hFEM-2 overexpression
(Fig. 7). These observations suggest that hFEM-2 may mediate its
pro-apoptotic effect through a signaling pathway that involves
caspase-9 and Bcl-XL.
Mutation Analysis of hFEM-2--
A study of the time course of
apoptosis mediated by hFEM-2 in HeLa cells showed that significant
apoptosis occurs only after 16 h (data not shown). At 6 or 10 h after transfection, cells transfected with 2 µg of hFEM-2 showed
only a marginal increase in number of pro-apoptotic cells (Fig.
8A). To delineate the
potential effector and regulatory domains of hFEM-2 responsible for the pro-apoptotic effect, HeLa cells were transiently transfected with
expression vectors encoding Myc-tagged hFEM-2 (2 µg) or various deletion mutants (Fig. 8A, left
panel). Cells transfected with hFEM-2-(94-454) or
hFEM-2-(157-454) displayed efficient pro-apoptotic activity at 6 and
10 h (Fig. 8A), suggesting that the catalytic domain of
hFEM-2 is required for its pro-apoptotic activity. Cells transfected
with the NH2-terminal domain of hFEM-2 alone (1)
showed no significant increase in apoptosis (Fig. 8A) even
after 24 h (data not shown), suggesting that the
NH2-terminal domain is inactive in apoptosis.
Interestingly, the NH2-terminal deleted constructs appeared
significantly more potent than wild type hFEM-2 in inducing apoptosis
(Fig. 8A), suggesting that the NH2-terminal
domain may have a negative regulatory function. The
NH2-terminal deleted mutants and full-length hFEM-2 all
exhibited similar levels of protein expression at 6 and 10 h (data
not shown), supporting the argument that the difference in
pro-apoptotic ability was not a consequence of variation of protein
expression. NH2-terminal deleted mutants of FEM-2, however,
showed pro-apoptotic activity similar to that of full-length FEM-2
(data not shown), suggesting that the negative regulatory function of
the NH2-terminal domain of FEM-2 had been acquired during
evolution.
The deletion mutants were also evaluated for their ability to associate
with F1A
The results of the deletion analysis suggest that the region
containing the catalytic domain of hFEM-2 is required for its pro-apoptotic activity. Because critical amino acid residues required for catalytic activity of PP2C phosphatases have been defined, we next
asked the question whether the phosphatase activity of hFEM-2 is
required for mediating apoptosis. hFEM-2 mutants were generated in
which Gly202 or Arg326 (Fig. 8B),
which are conserved residues that have been shown to be necessary for
PP2C activity (13, 41, 42), was mutated to Asp (G202D) or Ala (R326A),
respectively. As expected, the abilities of these mutants to
dephosphorylate the RRA(pT)VA peptide were diminished to essentially
background level in vitro (Fig. 8C,
left panel). A control mutant was also created
where the nonconserved amino acid Arg207 (Fig.
8B) was mutated to Ala (R207A). hFEM-2 (R207A) exhibited PP2C activity at a level similar to wild type hFEM-2 (Fig.
8C, left panel). The protein levels of
all the point mutants were similar to wild type (Fig. 8C,
lower panel). The G202D and R326A mutants that
showed reduced PP2C phosphatase activity were also unable to
dephosphorylate CaM kinase II in vitro (data not shown), whereas the R207A mutant dephosphorylated CaM kinase II to an extent
similar to that of wild type hFEM-2 (data not shown).
hFEM-2 and the R207A mutant that retained phosphatase activity both
mediated apoptosis to similar extents (Fig. 8C,
right panel). However, the R326A and G202D
mutants that lacked phosphatase activity failed to mediate apoptosis
beyond basal level (Fig. 8C, right
panel). All the point mutants of hFEM-2 were still able to
associate with both FEM-3 and F1A Our earlier observations that FEM-1 and its human homologue F1A Co-conservation of sequence and function is an important principle
during evolution. As a consequence, sequence-related genes often have
similar functions in evolutionarily distant species. Here we show that
FEM-2 and its mammalian homologues share similar functions as a PP2C
phosphatase and as a specific protein partner of FEM-3. Furthermore,
our characterization revealed several novel molecular functions of
FEM-2 and its mammalian homologues, namely 1) they associate physically
with FEM-1/F1A Although the catalytic domains of hFEM-2 and FEM-2 are required for
mediating apoptotic function, the NH2-terminal domain of
hFEM-2 appears to negatively regulate its pro-apoptotic activity. Interestingly, The NH2-terminal domain of F1A Protein phosphatases are known to regulate various cellular events such
as cell growth, differentiation, and apoptosis. Dephosphorylation appears to be an important regulatory step with respect to the kinase
activity of CaM kinases (22-25). Indeed, autophosphorylation of CaM
kinase II at Thr286 has been shown to be up-regulated in
ischemic tolerance (44), and loss of CaM kinase activity has been
suggested to play a role in initiating the changes leading to
ischemia-induced cell death (45). KN-93, a specific inhibitor of CaM
kinase II, induces apoptosis in NIH 3T3 cells (46). CaM kinase
inhibition has been shown to potentiate thapsigargin-mediated cell
death in SH-SY5Y cells (47). Furthermore, CaM kinase IV has been shown
to inhibit apoptosis induced by oxygen deprivation in cerebellar
granule neurons (48), suggesting that inhibition of CaM kinase activity might lead to apoptosis. Because CaM kinases have been implicated in
regulating apoptosis in various experimental paradigms, protein phosphatases that dephosphorylate CaM kinases may be important for
regulating apoptotic events. We show here that hFEM-2, FEM-2, and
rCaMKPase are all capable of dephosphorylating autophosphorylated CaM
kinase II and mediating apoptosis in HeLa and NIH3T3 cells, suggesting
that these CaM kinase phosphatases are involved in apoptosis signaling.
The ability to mediate apoptosis appears to require an intact
phosphatase domain as point mutants in which the phosphatase activity
was disrupted failed to induce apoptosis. CaM kinase kinase, the kinase
that phosphorylates the CaM kinases, has been implicated in activation
of PKB/Akt, a kinase in a cell survival signaling pathway (25). CaM
kinase phosphatases may promote cell death by antagonizing this action
of CaM kinase kinase.
FEM-2 is known genetically to be essential for the specification of
male development in C. elegans (12). Its phosphatase activity is required for its sex determination function, suggesting the
involvement of a kinase in directing the sexual fate of C. elegans (13). Currently, among all the sex-determining proteins in
C. elegans, no protein containing a kinase domain or
exhibiting kinase activity has been described. The
Ca2+/calmodulin-dependent protein kinase
cascade is conserved from C. elegans to mammals (49). The
observation that FEM-2 is a homologue of mammalian CaM kinase
phosphatase and that it dephosphorylates rat CaM kinase II Rapid divergence is common among sex-determining genes. Mammalian
SRY genes, for example, are highly divergent outside the HMG
domain (50, 51). Human and murine SRY proteins, although are functional
homologues, are not functionally interchangeable (52). The two genes
flanking fem-1 in the sex determination pathway,
tra-1 and tra-2, are the most highly diverged
genes known between the two Caenorhabditis species, C. elegans and C. briggsae (53, 54). Does hFEM-2 have a
role in sex determination? This possibility seems remote as C. briggsae fem-2, which has 45% amino acid identity to C. elegans fem-2, can only weakly rescue the FEM-2-deficient
phenotype in C. elegans (7), suggesting that, like many
other genes in the sex determination pathway, the sex determination
function of the fem-2 gene is rapidly evolving. Furthermore,
hFEM-2 displayed minimal activity in rescuing the FEM-2 deficient
phenotype in C. elegans.2 Significant
protein sequence conservation among sex-determining genes between phyla
is rare. However, recent evidence indicates that conservation of a
functional domain in a sex-determining protein among different species
may be sufficient to retain certain sex-determining function during
evolution. For example, the DM domains of the mab-3 gene in
C. elegans and the dsx gene of
Drosophila were found to have structural and functional
similarity (55), and the DM domain has sexual dimorphic expression
across C. elegans, Drosophila, and mammals (56).
These results suggest that at least some aspects of sexual regulation
have a common evolutionary origin. The precise physiological role of
mammalian homologues of FEM-2 awaits further investigation in CaM
kinase phosphatase deficient animals.
, has been described. Although there is little evidence to link F1A
to sex determination, F1A
and FEM-1 both promote apoptosis in mammalian cells. Here we report the identification and characterization of a
human homologue of the C. elegans sex-determining protein FEM-2, hFEM-2. Similar to FEM-2, hFEM-2 exhibited PP2C phosphatase activity and associated with FEM-3. hFEM-2 shows striking similarity (79% amino acid identity) to rat Ca2+/calmodulin
(CaM)-dependent protein kinase phosphatase (rCaMKPase). hFEM-2 and FEM-2, but not PP2C
, were demonstrated to dephosphorylate CaM kinase II efficiently in vitro, suggesting that hFEM-2
and FEM-2 are specific phosphatases for CaM kinase. Furthermore, hFEM-2 and FEM-2 associated with F1A
and FEM-1 respectively. Overexpression of hFEM-2, FEM-2, or rCaMKPase all mediated apoptosis in mammalian cells. The catalytically active, but not the inactive, forms of hFEM-2
induced caspase-dependent apoptosis, which was blocked by
Bcl-XL or a dominant negative mutant of caspase-9. Taken together, our
data suggest that hFEM-2 and rCaMKPase are mammalian homologues of
FEM-2 and they are evolutionarily conserved CaM kinase phosphatases that may have a role in apoptosis signaling.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
has recently been identified as a mammalian Fas death
domain-interacting protein in a yeast two-hybrid screen (15). Overexpression of F1A
induces apoptosis in mammalian cells, and F1A
is a caspase substrate (15). Interestingly, F1A
was found to
be highly homologous throughout its entire protein sequence, to the
C. elegans sex determination protein FEM-1 (15, 16). The
degree of similarity between FEM-1 and F1A
(30% amino acid identity) is comparable with that between several of the functionally conserved components of PCD in nematodes and mammals, e.g.
the amino acid identity between CED-9 and Bcl-2 is 23% (17), and that
between CED-3 and caspase-3 is 34% (18).
to sex determination function, FEM-1 and its mammalian
homologue, F1A
, were found to induce apoptosis when overexpressed in
mammalian cells (15, 16). In vitro experiments demonstrated
that FEM-1 is cleaved by the C. elegans caspase, CED-3,
demonstrating a striking parallel to its mammalian homologue, F1A
(16). It is possible that fem-1, in contrast to many other
sex-determining genes in C. elegans, was conserved during
evolution because of its function in apoptosis. The functional
conservation between FEM-1 and F1A
in mediating apoptosis in
mammalian cells raises an intriguing possibility that perhaps not only
FEM-1 but a subset of genes in the C. elegans sex
determination pathway may also be conserved if they have a role to play
in apoptosis signaling.
(20), does not.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
(20) were obtained by
polymerase chain reaction (PCR) amplification from human spleen
cDNA (CLONTECH) with the ExpandTM high fidelity
PCR system (Roche Molecular Biochemicals) with primers incorporated
with appropriate restriction sites and inserted into the pXJ40
mammalian expression vector driven by the CMV promoter (30). The
constructs were sequenced to ensure that no PCR error was introduced.
All epitope tags are at the NH2 termini. Point mutations
were introduced using the TransformerTM site-directed mutagenesis kit
(CLONTECH).
20 °C, washed twice with PBS, and permeabilized with 0.2%
Triton X-100 in PBS for 10 min, followed by four washes with PBS. Cells
were then blocked with 10% fetal bovine serum in PBS for 10 min and
incubated with mouse monoclonal anti-Myc antibody for 1 h,
followed by washing three times with PBS containing 0.1% Triton X-100.
Cells were then incubated with anti-mouse FITC-conjugated antibody for
1 h and washed three times with PBS containing 0.1% Triton X-100. Cells were then incubated with propidium iodide for 10 min to stain the
nuclei and washed three times with PBS. Cells were mounted in
anti-fading agent (Molecular Probes), placed on a glass slide, and
viewed using a confocal microscope.
-mercaptoethanol, 0.1% Triton X-100, 1 mM PMSF, 50 µg/ml aprotinin, and 10 µg/ml leupeptin). Lysates were subjected to immunoprecipitation using 3 µg of polyclonal anti-Myc antibodies. 20 µl of 1:1 slurry of protein A-agarose was added after 1 h and incubated for another 1 h at 4 °C. The agarose beads were
washed three times with storage buffer and resuspended in 50 µl of
storage buffer before incubating with the phosphothreonine peptide
substrate, RRA(pT)VA, and PP2C buffer (50 mM imidazole, pH
7.2, 0.2 mM EGTA, 20 mM MgSO4,
0.02%
-mercaptoethanol, 0.1 mg/ml BSA) at 30 °C for 1 h. In
experiments that determine cation requirement, MgSO4 is
replaced with the sulfates of the indicated cations. Free phosphate generated was then quantitated according to the instructions of the
Serine/Threonine Phosphatase Assay SystemTM (Promega).
-32P]ATP (6000 Ci/mmol). Excess EDTA (12.3 mM) and BSA (1 mg/ml) were added to stop the reaction, and
the reaction mixture was applied to a P30 microspin column (Bio-Rad)
buffered with 50 mM Tris, pH 7.5, 0.2 M NaCl,
0.05% Tween 20, and 1 mM dithiothreitol. The eluate from
the spin column was collected and stored at
80 °C.
, or immunoprecipitates of
Myc-hFEM-2, Myc-hFEM-2, or Myc vector, in 50 mM Tris-HCl,
pH 7.5, 100 mM KCl, 2 mM MgCl2, 2 mM MnCl2, 0.1 mM EGTA, 0.01% Tween
20, 10 µg/ml poly(Lys), and 28,000 cpm autophosphorylated
[32P]CaMKII. After preincubation for 30 s at
30 °C, the reaction was started by adding the phosphoprotein. Where
indicated, 1 mM orthovanadate or 25 mM EDTA was
added. After incubation for 20 min, the reaction was terminated by
mixing with SDS-PAGE sample buffer. The mixture was boiled for 2 min
and centrifuged for 2 min, and an aliquot of the supernatant was run on
a 10% SDS-PAGE. The gel was stained with Coomassie Blue to ensure
equal loading of protein, following which the gel was dried and
visualized by autoradiography.
using LipofectAMINETM. 24 h
after transfection, the cells were fixed, rinsed with PBS, and then
incubated for 2 min with Hoechst 33342 dye (Molecular Probes Inc.) to
enable nuclear staining. The cells were subsequently fixed and then
visualized using a Zeiss Axioplan microscope.
-galactosidase. Vector plasmid was
supplemented to bring the total amount of plasmids for each
transfection to 5 µg. Transfections were carried out with
LipofectAMINETM for 6 h, followed by change of medium, and ZVAD
added to the fresh medium at this point where indicated. 24 h
later, the cells were fixed with 2% formaldehyde and 0.2%
glutaraldehyde and stained with 5-bromo-4-chloro-3-indolyl
-D-galactopyranoside (X-gal) solution at 37 °C. Cells
were visualized by phase-contrast microscopy and blue
(
-galactosidase-positive) cells were scored for apoptotic
morphology. The data (mean ± S.D.) shown are percentage of round
blue cells as a function of total number of blue cells counted
(~400-500 cells/sample) from three to five randomly chosen fields.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (72K):
[in a new window]
Fig. 1.
Amino acid sequence alignment and
distribution of hFEM-2. A, the predicted amino
acid sequence of hFEM-2 is aligned with that of FEM-2 (9), by the
Jotun Hein method of the DNASTAR program. Shaded and
open boxes show identical and conserved amino
acids, respectively. The percentage identity is 28%, and the
percentage similarity is 37%. B, Northern blot analysis of
hFEM-2 mRNA in multiple human tissues. The Northern blots
(CLONTECH) of poly(A+) RNA (2 µg/lane) from adult human tissues were probed with a random primed
32P-labeled cDNA probe corresponding to amino acids
1-97 of hFEM-2. The bands that hybridized to the hFEM-2 probe are
indicated by arrows. The blots were subsequently stripped
and rehybridized with a
-actin probe. C, subcellular
localization of overexpressed hFEM-2. MCF-7 cells were transiently
transfected with plasmids encoding NH2-terminally tagged
Myc-hFEM-2. 16 h after transfection, the cells were fixed, rinsed
in PBS, and incubated with monoclonal anti-Myc antibody followed by
anti-mouse FITC-conjugated antibody. Cells that were transfected are
green. The nuclei of these cells were stained by propidium
iodide (red).
,
,
) (20, 32, 33) of PP2C family generally
share high degree of sequence similarity (34); however, the catalytic
domain of FEM-2 is more similar in sequence to that of hFEM-2 than to
other mammalian PP2Cs.
(20), PP2C
(32), and PP2C
(33).
In contrast to other protein phosphatases, the dephosphorylation
activity of PP2C absolutely requires the metal cations,
Mn2+ or Mg2+, but its activity is not sensitive
to the tumor promoter okadaic acid and other inhibitors of the PPP
family (34). Full-length NH2-terminal Myc-tagged hFEM-2,
FEM-2, or hPP2C
were transiently overexpressed in 293T cells. The
Myc-tagged proteins were immunoprecipitated using anti-Myc antibody,
and the immunoprecipitates were assayed for phosphatase activity
in vitro. The phosphatase activity was assayed by
dephosphorylating the phosphothreonine peptide RRA(pT)VA as described
under "Experimental Procedures." Immunoprecipitates of hFEM-2
protein from transiently transfected 293T cells exhibited phosphatase
activity to an extent similar to that of FEM-2 and PP2C
in the
presence of 20 mM Mg2+ or Mn2+
(Fig. 2A, lanes 3,
4, 7, and 8). However, in the presence
of 20 mM Ca2+ or in Mg2+-free
buffer, little phosphatase activity above basal level was detected
(Fig. 2A, lanes 2 and 5). The
dephosphorylation activity was not inhibited by okadaic acid (10 µM) (Fig. 2A, lane 6). Both hFEM-2
and FEM-2 displayed substrate concentration-dependent
kinetics as the phosphatase activities increased with increasing
substrate concentration (Fig. 2B). Taken together, these
data suggest that hFEM-2 is a PP2C phosphatase.

View larger version (24K):
[in a new window]
Fig. 2.
hFEM-2 exhibits PP2C phosphatase activity
toward the peptide substrate (RRA(pT)VA) in
vitro. A, hFEM-2 is a PP2C phosphatase.
Phosphatase activity was assayed as described under "Experimental
Procedures" using the phosphothreonine peptide RRA(pT)VA as
substrate. 293T cells growing on 100-mm plates were transfected with 10 µg of expression vector containing Myc-tagged hFEM-2, FEM-2, PP2C
,
or empty vector. 24 h after transfection, the cells were collected
and lysed in storage buffer. Immunoprecipitates of Myc-tagged proteins
(
2 µg) were incubated with 100 µM substrate in the
presence of 20 mM Mg2+, 20 mM
Mn2+, 20 mM Ca2+, 1 mM
EDTA, or 10 µM okadaic acid as indicated in
parentheses. The data shown (mean ± S.D.) are from
three independent experiments. B, the phosphatase activities
of FEM-2 and hFEM-2 exhibit substrate
concentration-dependent kinetics. Myc-FEM-2 (
),
Myc-hFEM-2 (
), or Myc vector control (
) were immunoprecipitated
using anti-Myc rabbit polyclonal antibody, and the immunoprecipitates
(
2 µg) were incubated with increasing concentrations of substrate
in the presence of 20 mM Mg2+ at 30 °C for
1 h. The data shown (mean ± S.D.) are from three separate
measurements of free phosphate released.
-casein, and phosphorylase a were not significantly dephosphorylated
(28), suggesting that it is a specific phosphatase that regulates CaM
kinases. While characterization of hFEM-2 was in progress, the cDNA
encoding rCaMKPase was isolated (21). Interestingly, the amino acid
sequence of rCaMKPase is 79% identical to that of hFEM-2 (Fig.
3A), suggesting that hFEM-2
may be the human orthologue of rCaMKPase. Similar to hFEM-2, rCaMKPase
shares 27% amino acid identity with C. elegans FEM-2,
suggesting that FEM-2 may also be a CaM kinase phosphatase.

View larger version (45K):
[in a new window]
Fig. 3.
hFEM-2 and FEM-2 dephosphorylate CaM kinase
II in vitro. A, hFEM-2 is highly
homologous to rCaMKPase. The predicted amino acid sequence of hFEM-2 is
aligned with that of rat CaM kinase phosphatase (21), by the Jotun Hein
method of the DNASTAR program. Amino acid residues in hFEM-2 that are
identical to that of rat CaM kinase phosphatase are represented by
dots. The percentage identity is 79%. B, hFEM-2
and FEM-2 dephosphorylate CaM kinase II in vitro. Equivalent
amounts of CaMKII (
10 ng), which had been pre-autophosphorylated
with [
-32P]ATP as described under "Experimental
Procedures," were incubated at 30 °C for 20 min with
2 µg of
GST protein and the indicated GST fusion proteins under the various
conditions as indicated in parentheses (lanes
2-10) or with immunoprecipitated Myc-tagged proteins as indicated
(lanes 11-13). Where indicated, 25 mM EDTA or 1 mM orthovanadate was added. Aliquots of the reactions were
analyzed by SDS-PAGE, followed by autoradiography. The position
corresponding to the
isoform of CaMKII is indicated
(upper panel). The gel was Coomassie-stained, and
the bands representing the various GST fusion proteins were aligned to
show equivalency of protein (lower panel,
lanes 1-10). The lower bands represent BSA, which migrated
very closely with the indicated GST fusion proteins on SDS-PAGE. BSA
was used to stop the CaM kinase II autophosphorylation reaction
(lower panel, lanes 2-10).
Immunoprecipitates of the Myc-tagged proteins were analyzed by SDS-PAGE
followed by Western blotting, probed using monoclonal anti-Myc
antibody, and aligned to show equivalency of protein (lower
panel, lanes 11-13).
GST fusion
proteins were tested for their ability to dephosphorylate autophosphorylated CaM kinase II in vitro. Equivalent
amounts of GST-rCaMKPase, GST-hFEM-2, and GST-FEM-2 were able to
dephosphorylate 32P-labeled, autophosphorylated CaM kinase
II (isoform
), in the presence of 10 µg/ml poly(Lys) (Fig.
3B, lanes 8, 2, and 5,
respectively). The activity of rCaMKPase has been shown to be greatly
stimulated by poly(Lys) (21, 28). Similar to rCaMKPase, in the absence of poly(Lys), the dephosphorylation activities of GST-hFEM-2 and GST-FEM-2 were significantly reduced (Fig. 3B, lanes 4 and
7). An equivalent amount of GST-hPP2C
, which exhibited
higher phosphatase activity toward the RRA(pT)VA substrate than
GST-hFEM-2 (data not shown), failed to dephosphorylate CaM kinase II in
the presence (Fig. 3B, lane 10) or absence of 10 µg/ml poly(Lys) (data not shown), suggesting that rCaMKPase, hFEM-2,
and FEM-2 are specific phosphatases for CaM kinases. In the presence of
25 mM EDTA, a chelator of Mg2+, GST-FEM-2,
GST-hFEM-2, and GST-rCaMKPase were unable to dephosphorylate CaM kinase
II (Fig. 3B, lanes 6, 3, and
9, respectively), suggesting that, like rCaMKPase (21, 28),
the CaM kinase phosphatase activities of FEM-2 and hFEM-2 are dependent
on Mg2+/Mn2+. In this assay, orthovanadate (1 mM), an inhibitor of many protein phosphatases, including
PP-1, PP2B, and PP2C (28), had no significant effect on the
dephosphorylation of CaM kinase II by GST-hFEM-2, GST-FEM-2, and
GST-rCaMKPase (data not shown). These data suggest that FEM-2 and its
mammalian homologues exhibit unique enzymatic properties toward CaM
kinases that distinguish them from other phosphatases.
. HA-FEM-3
co-immunoprecipitated with Myc-FEM-2, Myc-hFEM-2, and Myc-rCaMKPase,
but not Myc-PP2C
(Fig. 4A,
top panel). The lack of association of PP2C
with FEM-3 is not a consequence of low protein level, as immunoblot
analysis of immunoprecipitates of HA- and Myc-tagged proteins confirmed
similar levels of protein expression (Fig. 4A,
lower panels). HA-tagged FEM-3 did not form nonspecific immunoprecipitates with the anti-Myc antibody (data not
shown). Immunoprecipitation of Myc-tagged FEM-3 using anti-Myc antibody
also co-immunoprecipitated HA-tagged hFEM-2 (data not shown).

View larger version (18K):
[in a new window]
Fig. 4.
hFEM-2 interacts specifically with FEM-3
in vivo and in vitro.
A, hFEM-2 associates with FEM-3 in vivo in
mammalian cells. 293T cells were transiently co-transfected with
expression plasmids encoding HA-tagged FEM-3 (5 µg) and the indicated
Myc-tagged proteins (5 µg). 5 h after the change of medium, the
Myc-tagged proteins were immunoprecipitated (IP) with
polyclonal anti-Myc antibody (A-14). Co-immunoprecipitated HA-tagged
FEM-3 proteins were detected by immunoblot analysis using monoclonal
anti-HA antibody (top panel). Expression of
HA-tagged FEM-3 was determined by Western blot analysis of an aliquot
(1%) of the total extract (1 ml) with monoclonal anti-HA antibody
(F-7) (middle panel). After stripping the blot,
immunoprecipitated Myc-tagged PP2C proteins were detected using
monoclonal anti-Myc antibody (9E10), and the bands representing the
different Myc-tagged proteins were aligned (lower
panel). Both the blots of the top panel and the
lower panel were subjected to similar exposure time (5 min).
B, hFEM-2 associates with FEM-3 in vitro.
Equivalent amounts of 35S-labeled, in vitro
translated FEM-3 (5 × 105 cpm) were incubated with
purified GST fusion proteins immobilized on glutathione-Sepharose
beads. Retained 35S-FEM-3 protein was analyzed by SDS-PAGE
and autoradiography (upper panel). The gel was
Coomassie-stained, and the bands representing the various GST fusion
proteins were aligned to show equivalency of loading (lower
panel).
(Fig. 4B), suggesting that there is a direct association between hFEM-2 and FEM-3.
--
Genetic
analyses suggest that the three genes fem-1,
fem-2, and fem-3 act at the same level in a
mutually dependent fashion in the sex determination pathway in C. elegans (8, 9). Although FEM-2 associates with FEM-3 (13), the
molecular relationships between FEM-1 and FEM-2/FEM-3 remain undefined.
This prompted us to examine whether hFEM-2 and F1A
, which are
putative human homologues of FEM-2 and FEM-1, respectively, are able to
associate in vivo. 293T cells were transiently
co-transfected with expression plasmids encoding Myc-tagged hFEM-2,
rCaMKPase, or FEM-2 and HA-tagged F1A
. Immunoprecipitation of
Myc-hFEM-2, rCaMKPase, and FEM-2 from cell extracts with anti-Myc
antibody co-immunoprecipitated HA-F1A
(Fig.
5A, left
panel). Under similar conditions, Myc-hPP2C
failed to
co-immunoprecipitate F1A
(Fig. 5A, left
panel), suggesting that F1A
interacts specifically with
FEM-2 and its mammalian homologues. HA-tagged F1A
did not form
nonspecific immunoprecipitates with the anti-Myc antibody (Fig.
5A, left panel). Conversely, Myc-tagged F1A
also co-immunoprecipitated HA-hFEM-2, but not HA-PP2C
(data not shown). Myc-FEM-2 was also able to
co-immunoprecipitate HA-FEM-1 (Fig. 5A, right
panel) when overexpressed in mammalian cells, suggesting
that FEM-1 and FEM-2 may function as components of a signal
transduction protein complex.

View larger version (22K):
[in a new window]
Fig. 5.
hFEM-2 interacts specifically with
F1A
. A, left panel,
hFEM-2 associates with F1A
in vivo in mammalian cells.
293T cells were transiently transfected with expression plasmids
encoding HA-tagged F1A
(5 µg) and the indicated Myc-tagged
proteins (5 µg). 5 h after the change of media, the Myc-tagged
proteins were immunoprecipitated (IP) with polyclonal
anti-Myc antibody. Co-immunoprecipitated HA-tagged F1A
proteins were
detected by immunoblot analysis using monoclonal anti-HA antibody
(top panel). Expression of HA-tagged F1A
was
determined by Western blot (WB) analysis of an aliquot (1%)
of the total extract with monoclonal anti-HA antibody
(middle panel). Immunoprecipitated Myc-tagged
proteins were detected using monoclonal anti-Myc antibody after
stripping the blot and reprobing, and the bands representing the
Myc-tagged PP2C proteins were aligned (lower
panel). Both the blots of the top left
panel and the lower left panel were
subjected to similar exposure time (5 min). Right panel,
FEM-2 associates with FEM-1 in vivo in mammalian cells. 293T
cells were transiently transfected with expression plasmids encoding
HA-tagged FEM-1 (5 µg) and Myc-tagged FEM-2 (5 µg). The Myc-tagged
proteins were immunoprecipitated (IP) with polyclonal
anti-Myc antibody. Co-immunoprecipitated HA-tagged FEM-1 protein was
detected by immunoblot analysis using monoclonal anti-HA antibody
(top panel). Expression of HA-tagged FEM-1 was
determined by Western blot (WB) analysis of an aliquot (1%)
of the total extract with monoclonal anti-HA antibody
(middle panel). Immunoprecipitated Myc-tagged
FEM-2 was detected using monoclonal anti-Myc antibody (lower
panel). B, hFEM-2 associates with FEM-1 and
F1A
in vitro. Equivalent amounts of
35S-labeled, in vitro translated (5 × 105 cpm) FEM-1 (lanes 1 and 3) or
F1A
(lanes 2 and 4) were incubated with the
indicated purified GST fusion proteins immobilized on
glutathione-Sepharose beads. Retained 35S-FEM-1 or
35S-F1A
protein were analyzed by SDS-PAGE and
autoradiography (upper panel). The gel was
Coomassie-stained, and the bands representing the GST fusion proteins
were aligned to show equivalency of loading (lower
panel).
and FEM-1 in vitro. Both in
vitro translated F1A
and FEM-1 were found to associate with
GST-hFEM-2 but not GST-hPP2C
(Fig. 5B), suggesting direct
interaction between F1A
and FEM-1 with hFEM-2. In vitro
translated FEM-1 also bound to GST-FEM-2 (data not shown). Taken
together, these data suggest that FEM-2 specifically associates with
FEM-1 and that the association function between hFEM-2 and F1A
has
been conserved during evolution.
significantly enhanced the percentage of apoptotic cells compared with
GFP vector control (Fig. 6A), suggesting that apoptosis
mediated by FEM-2 and hFEM-2 is likely to be specific and not a general
effect of phosphatase activity from overexpressing a phosphatase in the
cell.

View larger version (28K):
[in a new window]
Fig. 6.
hFEM-2, rCaMKPase, and FEM-2 promote
apoptosis in HeLa cells. A, nuclear condensation assay.
HeLa cells were transfected with 2 µg of pEGFP, pEGFP-FEM-2,
pEGFP-hFEM-2, or pEGFP-hPP2C
. 18 h after transfection, the
cells were fixed, stained and observed using fluorescence microscopy.
The upper panels show cells expressing GFP, pEGFP-FEM-2,
pEGFP-hFEM-2, or pEGFP-hPP2C
(indicated by arrows). The
nuclei of these same cells (as indicated by the arrows) were
visualized by Hoechst staining and shown in the lower
panels. B, hFEM-2 mediates
caspase-dependent apoptosis. HeLa cells were transfected
with 2 µg of the indicated expression plasmids and 0.5 µg of
pCMV-
-galactosidase. 18 h after transfection, apoptosis assays
were performed as described under "Experimental Procedures." The
data (mean ± S.D.) shown are percentage of round blue cells as a
function of total number of blue cells. C, hFEM-2 induces
PARP cleavage in HeLa cells. HeLa cells were transiently transfected
with 10 µg Myc-vector, Myc-hFEM-2, Myc-rCaMKPase, or Myc-FEM-2.
30 h after transfection, whole cell extracts were prepared from
the cells and endogenous PARP was detected by Western blot analysis
using the rabbit polyclonal anti-PARP antibody, A20.
-galactosidase (0.5 µg) in HeLa cells. 18 h after
transfection, cells were stained for
-galactosidase activity to mark
the transfected cells and scored for apoptotic morphology as described
(15, 16). Overexpression of hFEM-2 and rCaMKPase significantly
increased the number of apoptotic cells as compared with cells
transfected with vector control (Fig. 6B). FEM-2, but not
hPP2C
, also mediated apoptosis in HeLa cells to an extent similar to
that for the mammalian CaMKPases (Fig. 6B). Cell death
mediated by hFEM-2 was efficiently blocked by 20 µM ZVAD
(Fig. 6B), suggesting that caspase activation may be
required for its activity. Similarly, cell death mediated by FEM-2 and
rCaMKPase was also efficiently blocked by 20 µM ZVAD (data not shown).
or FEM-3 failed to induce apoptosis in all
cell lines tested (data not shown), suggesting an absence of intrinsic
pro-apoptotic activity in these molecules

View larger version (13K):
[in a new window]
Fig. 7.
The pro-apoptotic activity of hFEM-2 is
blocked by Bcl-XL or dominant negative caspase 9. HeLa cells were
co-transfected with expression plasmids of hFEM-2 (1 µg), 2× molar
excess of plasmids expressing Bcl-XL, or the indicated dominant
negative mutants: caspase-8-DN (caspase-8-(1-415)), caspase-9-DN
(caspase-9(C287A)), and pCMV-
-galactosidase (0.5 µg) and assayed
for apoptosis 30 h after transfection. The data (mean ± S.D.) shown are percentage of round blue cells as a function of total
number of blue cells counted. At least three independent experiments
were performed for each combination of plasmids, and similar results
were observed.

View larger version (33K):
[in a new window]
Fig. 8.
Mutation analysis of hFEM-2.
A, pro-apoptotic activity of hFEM-2 and its deletion mutants
at 6- and 10-h time points. Empty and filled
bars indicate data at 6- and 10-h time points, respectively.
The horizontal bars on the left
represent the amino acid sequences of hFEM-2 and its deletion mutants.
B, Alignment of the conserved regions in the PP2C motifs of
various PP2C phosphatases. Identical amino acids are boxed
and positions of amino acid residues chosen to be mutated in hFEM-2 are
indicated by arrows. C, the enzymatic activity of
hFEM-2 is required for its pro-apoptotic function. The left
panel shows the phosphatase activity of hFEM-2 and its point
mutants. 293T cells were transfected with expression vector containing
hFEM-2 or its point mutants. 24 h after transfection, the cells
were collected and lysed in storage buffer. The Myc-tagged proteins
were immunoprecipitated using anti-Myc rabbit polyclonal antibody, and
the immunoprecipitates were incubated with 100 µM
phosphothreonine peptide substrate in the presence of 20 mM
Mg2+ at 30 °C for 1 h. Free phosphate generated was
measured spectrophotometrically according to the instructions of the
manufacturer (Promega). The right panel shows the extent of
apoptosis mediated by hFEM-2 and its point mutants. HeLa cells were
transfected with 2 µg of the indicated expression plasmids and 0.5 µg of pCMV-
-galactosidase. Apoptosis assays were performed as
described under "Experimental Procedures." The data (mean ± S.D.) shown are percentage of round blue cells as a function of total
number of blue cells. Aliquots of immunoprecipitates from 293T cells
were analyzed using monoclonal anti-Myc antibody to evaluate the level
of expression of various constructs. The lower panel shows
protein expression levels of hFEM-2 and its point mutants.
WT, wild type.
. Both the N157 and 157-454 (catalytic domain) mutants
associated with F1A
(data not shown). To examine whether the
association of hFEM-2 and F1A
is required for the apoptosis function, point mutants in the catalytic domain of hFEM-2 that selectively abolish the association but not the catalytic function of
the hFEM-2 protein need to be identified.
(data not shown), suggesting that
the mutations did not result in a disruption in the entire conformation
of the protein. A corresponding point mutant of FEM-2 (R336A), which
had been shown previously to lose activity as a phosphatase as well as
sex determination function (13), also lost pro-apoptotic activity in
HeLa cells (data not shown), suggesting that the catalytic activities
of FEM-2 and its mammalian homologues are required for their ability to
mediate apoptosis.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
are substrates of caspases and are able to mediate apoptosis have led
us to hypothesize that perhaps a subset of C. elegans sex-determining genes may be involved in apoptosis signaling. Our
search for mammalian homologues of other fem genes has led us to identify hFEM-2, a putative human homologue of FEM-2.
, 2) they are specific CaM kinase phosphatases, and 3)
they promote apoptosis in mammalian cells.
, but not
FEM-1, has also been observed to negatively regulate the pro-apoptotic function of F1A
(15, 16), supporting the hypothesis that mammalian
proteins are capable of more complex control than their homologues in
lower organisms. The presence of a negative regulatory domain that
inhibits pro-apoptotic function is not unique to hFEM-2 and F1A
. For
example, the pro-apoptotic activity of Bid, a member of the Bcl-2
family of cell death regulators, is also negatively regulated through
its NH2-terminal domain (43). The NH2-terminal deletion mutant, hFEM-2-(94-454), in contrast to wild type hFEM-2, was
pro-apoptotic in all three cell types tested (data not shown). This
observation raises the possibility that the lack of pro-apoptotic activity of wild type hFEM-2 in MCF-7 cells is because of its failure
to overcome the negative regulation conferred by the NH2 terminus in this particular cellular environment.
in
vitro, suggests that the C. elegans CaM kinases (CaM
kinase kinase/CaM kinase I) are potential substrates of FEM-2.
| |
ACKNOWLEDGEMENTS |
|---|
We are grateful to Dr. Andrew Spence (University of Toronto) and Dr. Dave Pilgrim (University of Alberta) for providing us with the cDNA for FEM-1, FEM-2, and FEM-3. We thank Dr. Hitoshi Fujisawa and Dr. Atsuhiko Ishida for providing us with the cDNA for rat CaM kinase phosphatase. We thank Drs. Andrew Spence, Dave Pilgrim, and Karen S. Y. Yee for critical reading of the manuscript.
| |
FOOTNOTES |
|---|
* This work was supported by grants from the National Science and Technology Board of Singapore.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EMBL Data Bank with accession number(s) AF305840.
These authors contributed equally to this work.
§ Adjunct staff member of the Dept. of Pharmacology, National University of Singapore. To whom correspondence should be addressed. Tel.: 65-8743740; Fax: 65-7791117; E-mail: mcbyuck@imcb.nus.edu.sg.
Published, JBC Papers in Press, September 14, 2001, DOI 10.1074/jbc.M105880200
2 D. Pilgrim, personal communication.
| |
ABBREVIATIONS |
|---|
The abbreviations used are: PCD, programmed cell death; PCR, polymerase chain reaction; GST, glutathione S-transferase; ORF, open reading frame; CaM, Ca2+/calmodulin; rCaMKPase, rat Ca2+/calmodulin-dependent kinase phosphatase; CaMKII, Ca2+/calmodulin-dependent kinase II; EGFP, enhanced green fluorescent protein; PARP, poly(ADP-ribose) polymerase; PAGE, polyacrylamide gel electrophoresis; BSA, bovine serum albumin; CMV, cytomegalovirus; HA, hemagglutinin; PBS, phosphate-buffered saline; FITC, fluorescein isothiocyanate; PMSF, phenylmethylsulfonyl fluoride.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Metzstein, M. M., Stanfield, G. M., and Horvitz, H. R. (1998) Trends Genet. 14, 410-416[CrossRef][Medline] [Order article via Infotrieve] |
| 2. | Vaux, D. L., and Korsmeyer, S. J. (1999) Cell 96, 245-254[CrossRef][Medline] [Order article via Infotrieve] |
| 3. | Hengartner, M. O. (1998) Nature 391, 440-442 |
| 4. | Horvitz, H. R. (1999) Cancer Res. 59, 1701s-1706s |
| 5. | Schafer, A. J., and Goodfellow, P. N. (1996) Bioessays 18, 955-963[CrossRef][Medline] [Order article via Infotrieve] |
| 6. |
Marin, I.,
and Baker, B. S.
(1998)
Science
281,
1990-1994 |
| 7. |
Hansen, D.,
and Pilgrim, D.
(1998)
Genetics
149,
1353-1362 |
| 8. | Hansen, D., and Pilgrim, D. (1999) Mech. Dev. 83, 3-15[CrossRef][Medline] [Order article via Infotrieve] |
| 9. | Kimble, J., Edgar, L., and Hirsh, D. (1984) Dev. Biol. 105, 234-239[CrossRef][Medline] [Order article via Infotrieve] |
| 10. | Doniach, T., and Hodgkin, J. (1984) Dev. Biol. 106, 223-235[CrossRef][Medline] [Order article via Infotrieve] |
| 11. | Spence, A. M., Coulson, A., and Hodgkin, J. (1990) Cell 60, 981-990[CrossRef][Medline] [Order article via Infotrieve] |
| 12. | Pilgrim, D., McGregor, A., Jackle, P., Johnson, T., and Hansen, D. (1995) Mol. Biol. Cell 6, 1159-1171[Abstract] |
| 13. |
Chin-Sang, I. D.,
and Spence, A. M.
(1996)
Genes Dev.
10,
2314-2325 |
| 14. | Ahringer, J., Rosenquist, T. A., Lawson, D. N., and Kimble, J. (1992) EMBO J. 11, 2303-2310[Medline] [Order article via Infotrieve] |
| 15. |
Chan, S. L.,
Tan, K. O.,
Zhang, L.,
Yee, K. S.,
Ronca, F.,
Chan, M. Y.,
and Yu, V. C.
(1999)
J. Biol. Chem.
274,
32461-32468 |
| 16. |
Chan, S. L.,
Yee, K. S.,
Tan, K. M.,
and Yu, V. C.
(2000)
J. Biol. Chem.
275,
17925-17928 |
| 17. | Hengartner, M. O., and Horvitz, H. R. (1994) Cell 76, 665-676[CrossRef][Medline] [Order article via Infotrieve] |
| 18. |
Xue, D.,
Shaham, S.,
and Horvitz, H. R.
(1996)
Genes Dev.
10,
1073-1083 |
| 19. | Gaudet, J., VanderElst, I., and Spence, A. M. (1996) Mol. Biol. Cell 7, 1107-1121[Abstract] |
| 20. | Mann, D. J., |